GigaGen Awarded U.S. BARDA Contract Valued Up To $135.2M To Develop Recombinant Polyclonal Antibody Therapies For Botulinum Neurotoxins And An Additional Biothreat
GigaGen Awarded U.S. BARDA Contract Valued Up To $135.2M To Develop Recombinant Polyclonal Antibody Therapies For Botulinum Neurotoxins And An Additional Biothreat
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs
該合同將在六年內提供1960萬美元的初始承諾，並支持兩個項目的藥物製造和第一階段臨床試驗，最高達到13520萬美元
GigaGen's recombinant polyclonals are part of Grifols' robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals
GigaGen的重組多克隆體是基立福強大創新策略和爲患者和醫療保健專業人員提供下一代抗體藥物承諾的一部分。
SAN CARLOS, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of Grifols, announced today that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The award, valued at up to $135.2 million, is to develop a recombinant polyclonal antibody therapy for botulinum neurotoxins (BoNT) and a second biothreat of interest to the agency that will be determined at a later time.
2024年10月3日，加利福尼亞州聖卡洛斯（SAN CARLOS）——生物技術公司GigaGen Inc.，該公司正在推進用於免疫缺陷、傳染病和耐藥癌症的具有變革性的抗體藥物，是基立福（Grifols）的子公司，今天宣佈其已獲得美國衛生及公衆服務部（HHS）戰略準備與反應管理局（ASPR）旗下的生物醫藥先進研究與發展局（BARDA）頒發的一項合同。這項價值高達13520萬美元的獎勵旨在開發用於肉毒神經毒素（BoNT）和機構感興趣的第二種生物威脅的重組多克隆抗體療法，該機構將在以後確定的時間進行
